$ (413,941,958)

On January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest in both Regentys Corporation (“Regentys”) and Olaregen Therapeutix Inc. (“Olaregen”). Regentys is a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York based regenereative medicine company that is preparing to lauch its proprietary, patented, wound conforming gel matrix, Excellagen, an FDA 510K Cleared wound healing product. The terms of the Regentys acquisition included on upfront payment of $400,000, plus $14,600,000 to be paid according to a milestone-based schedule. The terms of the Olaregen acquisition included on upfront payment of $400,000, plus $11,600,000 to be paid according to a milestone-based schedule.

Secured promissory note

$ 15,000,000

Majority interest

51.00%

Organization of Business and Going Concern (Details Narrative) - USD ($)	Jan. 07, 2019	Apr. 30, 2019	Oct. 03, 2018	Jan. 18, 2017
Accumulated deficit		$ (413,941,958)
Working capital deficiency		$ 25,000,000
Secured promissory note Description	On January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest in both Regentys Corporation (“Regentys”) and Olaregen Therapeutix Inc. (“Olaregen”). Regentys is a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York based regenereative medicine company that is preparing to lauch its proprietary, patented, wound conforming gel matrix, Excellagen, an FDA 510K Cleared wound healing product. The terms of the Regentys acquisition included on upfront payment of $400,000, plus $14,600,000 to be paid according to a milestone-based schedule. The terms of the Olaregen acquisition included on upfront payment of $400,000, plus $11,600,000 to be paid according to a milestone-based schedule.
Veneto Holdings, L.L.C.
Secured promissory note			$ 15,000,000
Hema Diagnostic Systems, LLC
Majority interest				51.00%